Amphastar P (AMPH)
Operating profit margin
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating income (ttm) | US$ in thousands | 196,987 | 180,839 | 131,389 | 119,316 | 107,497 | 93,917 | 95,458 | 81,195 | 69,887 | 48,514 | 27,262 | 13,780 | 10,954 | 7,831 | 6,718 | 10,613 | -39 | 1,750 | 1,896 | -2,018 |
| Revenue (ttm) | US$ in thousands | 644,395 | 601,313 | 540,886 | 518,641 | 498,987 | 484,851 | 476,920 | 455,116 | 437,768 | 412,802 | 384,035 | 368,178 | 349,846 | 337,308 | 334,014 | 327,255 | 322,357 | 328,664 | 324,070 | 316,063 |
| Operating profit margin | 30.57% | 30.07% | 24.29% | 23.01% | 21.54% | 19.37% | 20.02% | 17.84% | 15.96% | 11.75% | 7.10% | 3.74% | 3.13% | 2.32% | 2.01% | 3.24% | -0.01% | 0.53% | 0.59% | -0.64% |
December 31, 2023 calculation
Operating profit margin = Operating income (ttm) ÷ Revenue (ttm)
= $196,987K ÷ $644,395K
= 30.57%
Amphastar Pharmaceuticals Inc has shown a consistently strong operating profit margin trend over the past eight quarters. In Q4 2023, the operating profit margin reached a high of 30.57%, indicating that the company generated approximately 30.57 cents of operating profit for each dollar of sales. This represents an improvement from the previous quarter, Q3 2023, where the margin was slightly lower at 30.07%.
Looking at the year-over-year comparison, the operating profit margin has steadily increased from 21.54% in Q4 2022 to 30.57% in Q4 2023. This demonstrates a positive growth trajectory in the company's operational efficiency and profitability.
It is worth noting that despite a slight dip in Q2 2023 and Q1 2023, the operating profit margin remained above 20%, indicating that the company has been able to effectively manage its operating expenses and generate healthy profits relative to its sales. This consistent performance reflects Amphastar Pharmaceuticals Inc's ability to maintain a strong financial position and effectively translate its revenue into operating profits.
Peer comparison
Dec 31, 2023